

Generet Award for Rare Diseases 2020

REGULATIONS



- Art. 1 On the initiative of the Fund Generet managed by the King Baudouin Foundation, **a prestigious Award will be granted to support a research project in the field of rare diseases.**
- Art. 2 Rare diseases are considered to be life threatening or chronic conditions which affect no more than 1 person out of 2.000. For this call, rare cancers and rare adverse drug events will not be taken into account.
- Art. 3 The Award amounts to 1.000.000 € over 4 years. However, a first installment of 500.000 € will be credited for 2 years and a second installment of 500.000 € will be subjected to a positive evaluation through a mid-term scientific, financial and communication report.
- Art. 4 Eligible expenses encompass personnel costs, running costs and equipment.
- Art. 5 Portability of the Award: The holder could keep the benefit of the Award if he/she transfers his/her research activities to another eligible Belgian institution (cf. below). The Award cannot follow the holder if he/she transfers his/her research activity to a private company or abroad.
- Art. 6 Eligibility rules pertaining to the applicant:
 - The applicant must be an internationally established investigator, with outstanding scientific achievements and multiple seminal contributions to our understanding of health and disease. The Award is open to a scientist with or without a track record in the field of rare diseases, but the research project has to be in the field of rare diseases.
 - The applicant must hold a PhD or have at least 4 years of equivalent research experience in a relevant field.
 - The applicant must be affiliated to a Belgian University or a Belgian University Hospital or an eligible Research Institute (cf. list in annex 1).
 - The applicant must provide the evidence of his/her affiliation to his/her institution until December 31, 2025 and not reaching the retirement limit during the project.
- Art. 7 The research project should aim at a better understanding of the processes (causes and mechanisms) underpinning rare diseases and translating fundamental discoveries into better prevention, diagnosis or treatment for patients. Research can encompass all stages from bench to bedside.

- Art. 8 Beyond a better understanding of the disease, translation of the research results into benefit for the patients is a key objective of the Fund Generet. As such, a clear description of the translational strategy will be considered as a strong asset.
- Art. 9 The following aspects of the research project are encouraged and considered as valuable assets (though they are not strictly mandatory):
 - Multidisciplinarity: referring to the use and application of different scientific disciplines as a substantial element of the research methodology.
 - Multicentric cooperation: referring to the close collaboration with centers of excellence located in Belgium or abroad. In case of international collaboration, the researcher working in the Belgian Institution must remain the coordinator of the project. However, **up to 30% of the Grant's amount could be outsourced for supporting international expenses** (personnel costs and running costs).
- Art.10 The Award will be granted by the Steering Committee of the Fund Generet on basis of the recommendation of an international and independent Jury. A representative of the Fund Generet will attend the Jury meeting as Observer. The role of the Observer is to ensure the respect of the procedure and the philosophy of the Prize. He will have no vote in the decision by the Jury.
- Art. 11 The Award cannot be divided amongst several laureates. If no suitable candidate can be identified, the Award will not be granted.
- Art. 12 Applications have to be submitted electronically on **April 20, 2020** at the latest. The form is available on the web platform www.generetaward.be. The form has to be filled using English.
- Art. 13 Any problems or disputes arising from the eligibility of submitted applications or from granting the Award will be settled by the Fund Generet, whose decision in these respects will be final.
- Art. 14 The scientific outline, presentations and evaluation reports generated in the frame of the Generet Award for Rare Diseases 2020 will be treated confidentially.